ESR1 and breast cancer: In the case of CDK4/6 these are the D type cyclins (4, 5) which are transcriptional targets of ERα (6) and frequently upregulated in ER+ breast cancer (7), providing the rationale for targeting this axis in ER+ breast cancer.